Escitalopram is a weak inhibitor of the cyp2d6-catalyzed o-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 6, 2009, Pages 626-633

  Noehr Jensen, L ^a   Zwisler, S T ^a,b   Larsen, F ^c   Sindrup, S H ^b   Damkier, P ^a,b   Brosen, K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; ESCITALOPRAM; O DEMETHYLASE; PLACEBO; TRAMADOL;

ADULT; ANALGESIC ACTIVITY; ARTICLE; BLOOD SAMPLING; COLD PRESSOR TEST; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOALGESIA; MALE; NAUSEA; PAIN; PHARMACODYNAMICS; PRIORITY JOURNAL; PUPILLOMETRY; UNSPECIFIED SIDE EFFECT;

ADULT; ANALGESICS, OPIOID; BIOTRANSFORMATION; CITALOPRAM; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DEALKYLATION; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; PAIN; PAIN MEASUREMENT; REFLEX, PUPILLARY; SEROTONIN UPTAKE INHIBITORS; TRAMADOL; YOUNG ADULT;

EID: 70450240778     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.154     Document Type: Article

References (35)

1. Owens, M.J. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J. Clin. Psychiatry 65 (suppl 4),5-10 (2004).
2. Cipriani, A. et al. Comparative efcacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373, 746-758 (2009).
3. Noehr-Jensen, L. et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur. J. Clin. Pharmacol. (2009); e-pub ahead of print 29 April 2009.
4. von Moltke, L.L., Greenblatt, D.J., Giancarlo, G.M., Granda, B.W., Harmatz, J.S. & Shader, R.I. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory efects, and comparison to R-citalopram. Drug Metab. Dispos. 29, 1102-1109 (2001).
5. Skjelbo, E. & Brøsen, K. Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34, 256-261 (1992).
6. Crewe, H.K., Lennard, M.S., Tucker, G.T., Woods, F.R. & Haddock, R.E. The efect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34, 262-265 (1992).
7. Sindrup, S.H., Brøsen, K., Hansen, M.G., Aaes-Jørgensen, T., Overø, K.F. & Gram, L.F. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug Monit. 15, 11-17 (1993).
8. Jeppesen, U., Gram, L.F., Vistisen, K., Loft, S., Poulsen, H.E. & Brøsen, K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fuoxetine, fuvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51, 73-78 (1996).
9. Brøsen, K. & Naranjo, C.A. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur. Neuropsychopharmacol. 11, 275-283 (2001).
10. Preskorn, S.H. et al. Comparison of duloxetine, escitalopram, and sertraline efects on cytochrome P450 2D6 function in healthy volunteers. J. Clin. Psychopharmacol. 27, 28-34 (2007).
11. Bair, M.J., Robinson, R.L., Katon, W. & Kroenke, K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 163, 2433-2445 (2003).
12. Roughead, E.E., McDermott, B. & Gilbert, A.L. Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans. Aust. NZ J. Psychiatry. 41, 366-370 (2007). (Pubitemid 46705733)
13. Klotz, U. Tramadol-the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 53, 681-687 (2003).
14. Poulsen, L., Arendt-Nielsen, L., Brøsen, K. & Sindrup, S.H. The hypoalgesic efect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 60, 636-644 (1996).
15. Stamer, U.M. et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105, 231-238 (2003).
16. Laugesen, S., Enggaard, T.P., Pedersen, R.S., Sindrup, S.H. & Brøsen, K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic efect of tramadol. Clin. Pharmacol. Ther. 77, 312-323 (2005).
17. Enggaard, T.P. et al. The analgesic efect of codeine as compared to imipramine in diferent human experimental pain models. Pain 92, 277-282 (2001).
18. Jones, S.F., McQuay, H.J., Moore, R.A. & Hand, C.W. Morphine and ibuprofen compared using the cold pressor test. Pain 34, 117-122 (1988).
19. Hindmarch, I. Instrumental assessment of psychomotor functions and the efects of psychotropic drugs. Acta Psychiatr. Scand. Suppl. 380, 49-52 (1994).
20. Fliegert, F., Kurth, B. & Göhler, K. The efects of tramadol on static and dynamic pupillometry in healthy subjects-the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur. J. Clin. Pharmacol. 61, 257-266 (2005).
21. Kirchheiner, J., Keulen, J.T., Bauer, S., Roots, I. & Brockmöller, J. Efects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J. Clin. Psychopharmacol. 28, 78-83 (2008).
22. US Food and Drug Administration. Drug Development and Drug Interactions (2006-2009). Lexapro (escitalopram oxalate) [prescribing information]. St Louis MO: Forest Pharmaceuticals, 2008. 〈http://www.frx.com/pi/lexapro-pi. pdf〉.
23. Wingen, M., Bothmer, J., Langer, S. & Ramaekers, J.G. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J. Clin. Psychiatry 66, 436-443 (2005).
24. Paul, M.A., Gray, G.W., Love, R.J. & Lange, M. SSRI efects on pyschomotor performance: assessment of citalopram and escitalopram on normal subjects. Aviat. Space Environ. Med. 78, 693-697 (2007).
25. Knaggs, R.D., Crighton, I.M., Cobby, T.F., Fletcher, A.J. & Hobbs, G.J. The pupillary efects of intravenous morphine, codeine, and tramadol in volunteers. Anesth. Analg. 99, 108-112 (2004).
26. Smith, S.A. Pupil function: tests and disorders. In Autonomic Failure (eds. Bannister, R. & Mathias, C.J.) 421-441 (Oxford University Press, Oxford, 1993).
27. Pedersen, R.S., Damkier, P. & Brøsen, K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur. J. Clin. Pharmacol. 62, 513-521 (2006).
28. Grond, S. & Sablotzki, A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 43, 879-923 (2004).
29. Chang, M., Dahl, M.L., Tybring, G., Götharson, E. & Bertilsson, L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5, 358-363 (1995).
30. Pedersen, R.S., Damkier, P. & Brosen, K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin. Pharmacol. Ther. 77, 458-467 (2005).
31. Pedersen, R.S., Brøsen, K. & Nielsen, F. Enantioselective HPLC method for quantitative determination of tramadol and O-desmethyltramadol in plasma and urine: application to clinical studies. Chromatographia 57, 279-285 (2003).
32. Hindmarch, I. The Leeds Psychomotor Tester (The University of Leeds, Leeds, UK, 1981).
33. Enggaard, T.P., Klitgaard, N.A., Gram, L.F., Arendt-Nielsen, L. & Sindrup, S.H. Specifc efect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin. Pharmacol. Ther. 69, 245-251 (2001).
34. McCulloch, C.E. Repeated measures ANOVA, R.I.P.? Chance 18, 29-33 (2005).
35. Oberg, A.L. & Mahoney, D.W. Linear mixed efects models. Methods Mol. Biol. 404, 213-234 (2007).